Toggle light / dark theme

Analyses of the viral genome are already providing clues to the origins of the outbreak and even possible ways to treat the infection, a need that is becoming more urgent by the day: Early on Saturday in China, health officials reported 15 new fatalities in a single day, bringing the death toll to 41. There are now nearly 1,100 confirmed cases there.

Reading the genome (which is made of RNA, not DNA) also allows researchers to monitor how 2019-nCoV is changing and provides a roadmap for developing a diagnostic test and a vaccine.

“The genetics can tell us the true timing of the first cases” and whether they occurred earlier than officials realized, said molecular biologist Kristian Andersen of Scripps Research, an expert on viral genomes. “It can also tell us how the outbreak started — from a single event of a virus jumping from an infected animal to a person or from a lot of animals being infected. And the genetics can tell us what’s sustaining the outbreak — new introductions from animals or human-to-human transmission.”

The Pennsylvania-based biotechnology company said early Thursday that it was awarded a grant of up to $9 million by the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for the new strain of coronavirus, 2019-nCoV, which originated in Wuhan, China, and has killed no less than 17 people.

Kim said after the DNA sequence of the new coronavirus strain was made publicly available on Jan. 11, Inovio was able to design and construct a potential vaccine in “a matter of hours,” and the animal-testing process has already begun.


As the coronavirus out of China spreads and gets deadlierof health care companies that announce plans to take part in finding a vaccine, or identifying patients with the new strain, have rallied sharply in very active trading.

On Thursday, among the bigger coronavirus gainers was Inovio Pharmaceuticals Inc.’s stock INO +10.42%, which ran up 12% to the highest close since May 9. Trading volume swelled to 12.3 million shares, compared with the full-day average over the past 30 days of about 1.4 million shares, according to FactSet.

The first case of novel coronavirus was confirmed in Orange County Saturday, health officials said.

The Orange County Health Care Agency’s Communicable Disease Control Division, which received confirmation from the Centers for Disease Control and Prevention, said the infected person is a traveler from Wuhan, China.

The respiratory disease has sickened 1,975 people and killed 56, almost all in Wuhan.

CHICAGO/LONDON (Reuters) — When a newly organized vaccine research group at the U.S. National Institutes of Health (NIH) met for the first time this week, its members had expected to be able to ease into their work. But their mandate is to conduct human trials for emerging health threats — and their first assignment came at shocking speed.

Circa 2019 Event 201, hosted by the Johns Hopkins Center for Health Security, envisions a fast-spreading coronavirus with a devastating impact.

Back in 2001, it was a smallpox outbreak, set off by terrorists in U.S. shopping malls. This fall, it was a SARS-like virus, germinating quietly among pig farms in Brazil before spreading to every country in the world. With each fictional pandemic Johns Hopkins experts have designed, the takeaway lesson is the same: We are nowhere near prepared.


Event 201 simulation hosted by university’s Center for Health Security envisions a fast-spreading coronavirus with a devastating impact.

Probiotics are live microorganisms, usually bacteria, that can be consumed to offer health benefits.

The ability of certain microbes to confer health benefits on their host was recognized more than 100 years ago. In 1904, Elie Metchnikoff, a scientist at the Pasteur Institute, claimed that Bulgarian peasants lived longer by eating yogurt made from bacteria that served to ferment the milk. Parisians rushed out to buy yogurt in response.

However, the huge variety of bacteria living on the planet was not appreciated back then. More recently, the development of technology that identifies organisms from their DNA has allowed scientists to show that plants, animals, insects and humans can be hosts for many different types of microorganisms.

To better understand the dynamics of bats and potential threats to human health, Goldberg and his colleagues explored the relationship of an African forest bat, a novel virus and a parasite. Their work, described in a report published July 13 in Nature Scientific Reports, identifies all three players as potentially new species, at least at the molecular level as determined by their genetic sequences.

Many viral pathogens often have more than one or two hosts or intermediate hosts needed to complete their life cycles. The role of bat parasites in maintaining chains of viral infection is little studied, and the new Wisconsin study serves up some intriguing insights into how viruses co-opt parasites to help do the dirty work of disease transmission.

The parasite in the current study is an eyeless, wingless fly, technically an ectoparasite. It depends on the bat to be both its eyes and wings. And it plays host to a virus, as the current study shows. For the virus, the fly plays the role of chauffeur. “From a virus’s perspective, an ectoparasite is like Uber. It’s a great way to get around — from animal to animal — at minimal expense and effort,” Goldberg explains.

Study reveals interplay of an African bat, a parasite and a virus


Since the emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrom Coronavirus (MERS-CoV) it has become increasingly clear that bats are important reservoirs of CoVs. Despite this, only 6% of all CoV sequences in GenBank are from bats. The remaining 94% largely consist of known pathogens of public health or agricultural significance, indicating that current research effort is heavily biased towards describing known diseases rather than the ‘pre-emergent’ diversity in bats. Our study addresses this critical gap, and focuses on resource poor countries where the risk of zoonotic emergence is believed to be highest. We surveyed the diversity of CoVs in multiple host taxa from twenty countries to explore the factors driving viral diversity at a global scale. We identified sequences representing 100 discrete phylogenetic clusters, ninety-one of which were found in bats, and used ecological and epidemiologic analyses to show that patterns of CoV diversity correlate with those of bat diversity. This cements bats as the major evolutionary reservoirs and ecological drivers of CoV diversity. Co-phylogenetic reconciliation analysis was also used to show that host switching has contributed to CoV evolution, and a preliminary analysis suggests that regional variation exists in the dynamics of this process. Overall our study represents a model for exploring global viral diversity and advances our fundamental understanding of CoV biodiversity and the potential risk factors associated with zoonotic emergence.